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Abstract
Act will replace national regulations that are based on the current system of medical devices directives (“MDD”). The 
Act on Medical Devices currently in force will be repealed and replaced by a new Act (the draft is currently being con-
sulted). The new regulations will change the conditions for observational, non-interventional studies in which medical 
devices are used as intended by the manufacturer (in-label). Today’s law provides for a liberal approach to this type of 
studies, but from May 2020 they will be treated like full clinical trials, except for the obligation to obtain administrative 
permission. The article describes this problem and also provides arguments supporting the thesis that such research 
will not require the prior opinion of the bioethics committee.
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On 26 May 2020, Regulation 2017/745 of the European 
Parliament and of the Council of 5 April 2017 on Medical 
Devices [1] (“MDR”) becomes fully applicable in all Mem-
ber States of the European Union, including Poland. This 
Act will replace all national laws that were enacted as 
measures of harmonisation introduced by the system of 
medical devices directives (MDDs) — i.e. Council Directive 
90/385/EEC of 20 June 1990 on the approximation of the 
laws of the Member States relating to active implantable 
medical devices [2] and Council Directive 93/42/EEC of 
14 June 1993 concerning medical devices [3]. This means 
that Poland’s current Act on Medical Devices 2010 [4] will 
be repealed and replaced by the new law. The draft new 
bill (hereinafter referred to as ‘The Draft Law’) has been 
recently published by the Ministry for Health and made 
available for public consultation.
Regulation 2017/745 (MDR) provides for a complex 
set of rules relating to clinical trials and the standards 
of clinical evaluation of medical devices. This new law 
is particularly important in two contexts. Firstly, the 
Regulation directly addresses the standard of clinical 
evidence necessary in order to deem the medical de-
vice compliant with minimal legal requirements. These 
standards are significantly raised when compared to the 
previous legal framework (binding under the system of 
MDD directives).
Secondly, MDR introduces a legal obligation to create 
and uphold a post-marketing clinical follow-up system 
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authorisation holder voluntarily or pursuant to legal 
obligations. In spite of a certain degree of ambiguity as 
concerns legal terminology [6], the Polish Pharmaceutical 
Act [7] provides for an even more farfetched rule. The 
said Act renders the entire body of regulation dedicated 
to pharmaceutical clinical trials inapplicable with respect 
to non-interventional, observational, in-label studies 
(subject to certain restrictions such as off-label studies 
— see article 37al of the Pharmaceutical Act) [8]. This 
means for example that under the Polish Pharmaceuti-
cal Act, an observational study of patients treated with 
acetylsalicylic acid in cardiovascular disease prevention, 
according to the medical standards, in-label and with no 
additional monitoring procedures, will not trigger any legal 
obligations that would normally be applied in the case of 
full-scope clinical trials.
Under the new medical devices regulations, things look 
quite different now. Article 74 of MDR sets out the legal 
rules that apply to a situation where a clinical investiga-
tion regards a device bearing the CE marking. It makes 
a distinction between two classes of situation: the first 
one where CE marking bearing device is to be investigated 
outside the scope of its intended purpose (off-label), and 
the second one where CE marking bearing device is to be 
investigated within the scope of its intended purpose, i.e. 
purpose set out by the producer (in-label). This latter is 
defined as ‘PMCF investigation’ (PMCF stands for ‘post-
-marketing clinical follow-up’). With respect to the first 
situation (example: use of cardiovascular stents in deep 
artery of penis angioplasty), the new law says simply that 
such investigations must be treated as clinical investiga-
tions and all legal requirements must be met. This makes 
sense, as off-label assessment of a medical device creates 
risk for patients ex definitione.
The provision relating to PMCF investigation, however, 
is somewhat trickier in its wording. The body of legal 
text stipulates that “if the investigation would involve 
submitting subjects to procedures additional to those 
performed under the normal conditions of use of the 
device and those additional procedures are invasive or 
burdensome, the sponsor shall notify the Member States 
concerned at least 30 days prior to its commencement 
by means of the electronic system […]” and “the content 
of such notification must include documentation set out 
in Chapter II of Annex XV as part of the notification, dea-
ling with specific requirement of clinical investigation”. 
The last sentence of the first section of article 74 says 
moreover that rules provided in points (b) to (k) and (m) 
of article 62(4), article 75, article 76, article 77, article 
80(5) and (6) and the relevant provisions of Annex XV 
shall apply to all PMCF investigations. This must be un-
derstood to be covering both PMCF investigations that 
are accompanied by invasive or burdensome procedures 
(PMCF). The Regulation lays down detailed rules for PCMF, 
in particular in the field of high class devices (IIa, IIb and 
III). PCMF includes clinical review and post-marketing 
studies performed by the producers with respect to their 
products.
The requirements for clinical investigation in MDR 
are based on existing ethical and legal regulations. 
The new provisions adhere to general good clinical 
practice, the Helsinki Declaration and other important 
foundations of modern clinical trials (see point 64 of 
the preamble to MDR). Specific and customised rules 
have been enacted to protect the interests of groups of 
patients such as pregnant and breastfeeding women, 
minors, and incapacitated subjects. Moreover, the MDR 
provides for regulation of inclusion of patients in a state 
of emergency. The regulation of the “clinical experiment 
as ultima ratio” issue is especially welcome — especially 
when there is no equivalent rule under Polish law and 
many patients are denied access to last resort methods 
or technologies only due to the lack of a legal option in 
this respect.
The clinical investigation measures set out in MDR 
are not controversial — both in light of the existing EU 
and Polish law. This paper calls for attention with respect 
to the issue regulated in a less transparent way — i.e. 
the legal status of purely observational studies with no 
experimental component.
To clear the grounds for discussion, several legal terms 
need to be explained in detail. The term ‘clinical investiga-
tion’ was a widely used, although non-defined, term under 
MDD system. Under art. 2 of MDR it means “any systematic 
investigation involving one or more human subjects, un-
dertaken to assess the safety or performance of a device”. 
‘Clinical evaluation’ is to be defined as “a systematic and 
planned process to continuously generate, collect, ana-
lyse and assess the clinical data pertaining to a device 
in order to verify the safety and performance, including 
clinical benefits, of the device when used as intended by 
the manufacturer”. The new wordings clearly indicate that 
the lawmakers wished to disengage from their semantic 
range experimental activities in cases aiming primarily 
at saving an individual patient’s life or health as well as 
to keep ‘under one roof’ different scientific methods, i.e. 
not to limit ‘clinical investigation’ to large, randomised, 
double-blinded clinical trials sensu stricto.
The new law does not recognise the observational 
and non-interventional study as a sub-type of clinical 
investigation. This approach differs greatly from the one 
taken in pharmaceutical law. Article 107m and other pro-
visions of the Directive 83/2001 on medicinal products 
for human use [5] specifically address and regulate non-
-interventional post-authorisation safety studies which 
are initiated, managed or financed by the marketing 
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as well as those investigations that are free of such 
additional measures.
To make the matter clearer, it might be useful to 
consider an example of a study of a transcatheter aortic 
valve replacement procedure where the only endpoint 
is time of procedure vs. clinical appraisal of the patient 
before surgery (using some available scale) and the hy-
pothesis is that a given technology is more time-efficient 
than eligible comparators. Such a study would aim at 
an appraisal of efficiency of a medical device already 
available on the market, bearing CE markings (PMFC). 
However, it would not yield any additional risk for the 
patient, as no additional interventional procedures are 
applied and the equipment is used inside the scope of 
intended purpose (in-label).
Therefore, what strikes MDR’s reader in this respect 
is the fact that the discussed provisions leave completely 
unattended all those situations where the CE marked de-
vice is investigated within the scope of intended purpose 
(in-label) and the study protocol is free of any invasive or 
burdensome procedures — where there is no shift in risk 
for the study subject whatsoever compared to the normal 
use of the device. This type of clinical investigation is very 
important in all fields of medicine, including cardiology and 
cardio-surgery. These studies do not create any additional 
risk for patients and may yield useful information — from 
epidemiological [9], clinical [10] and pharmaco-economic 
perspectives [11].
Under the existing Polish Medical Devices Act, the issue 
is regulated in the following manner. Article 40 section 
3 states that “a designed and planned systematic study 
of the device bearing CE marking in humans shall not be 
deemed a clinical trial if it is entered into with the aim of 
verifying safety or efficacy of the device and the studied 
device is used in accordance with its intended purpose”1. 
This means that the Polish law (still in force up to 25 May 
2020) provides for an absolutely different approach to 
observational, non-interventional, in-label studies. The 
current law does not consider such studies to be a part of 
the box labelled ‘clinical investigations’ [12]. The result is 
that no clinical investigation requirements are applicable 
to such investigational activities [13].
Notwithstanding the current approach, under MDR 
it must be assumed that in-label, observational, non-
-interventional studies will still be caught by the general 
definition of ‘clinical investigation’. This means that all 
obligations set out in MDR with respect to PMCF investiga-
tion must be observed, notwithstanding the fact that such 
studies are limited in their scope, and yield no additional 
risk to patients. The said provisions of the Regulation 
cover the requirement to acquire informed consent from 
the patient. Moreover, they provide for the obligation that 
the sponsor must be established in the European Union, 
that anticipated benefits to the subjects or to public he-
alth justify the foreseeable risks and inconveniences and 
compliance with this condition is constantly monitored, 
that the rights of the subject to physical and mental in-
tegrity, to privacy and to the protection of their data are 
safeguarded, that medical care provided to the subjects is 
the responsibility of an appropriately qualified healthcare 
professional, and that no undue influence, including that of 
a financial nature, is exerted on the subject to participate 
in the clinical investigation.
As concerns the ethics committee’s opinion, article 
62 section 4 letter (b) of the Regulation (that applies to all 
PMCF investigations) requires that, with respect to a given 
investigation, it is verified that “an ethics committee, set up 
in accordance with national law, has not issued a negative 
opinion in relation to the clinical investigation, which is valid 
for that entire Member State under its national law”. The 
discussed provision of MDR refers to national laws on ethics 
committees — in the case of Poland, the Medical Profession 
Act [14]. However, under the said Act, hardly can there be 
found any legal obligation to acquire a prior opinion of the 
ethics committee in the case of in-label, observational, 
non-interventional studies in medical devices. Such a stu-
dy is not covered by the definition of medical experiment.
This observation is very important because the borders 
for legal medical experiments are defined very narrowly 
under the Polish legal regime [15]. No other provision of 
Polish law would require the investigator or sponsor to seek 
the ethics committee’s approval before commencement 
of the discussed type of study.
To conclude, the MDR’s premise of a “lack of negative 
opinion” will be met with respect to observational, non-
-interventional, in-label investigations, even in a case whe-
re no ethics committee’s opinion is obtained whatsoever. 
However, all other premises, including patient consent, 
must be met, and this will necessitate a change in the 
Polish practice of the said investigations with respect to 
medical devices, including those used in cardiosurgical 
procedures.
1“A planned systemic investigation of the CE-marked medical device in 
humans, aiming at assessment of efficacy or safety of the device, is not 
to be considered a ‘clinical investigation’ if the medical device under 
scrutiny is used in accordance with its intended purpose”
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Streszczenie
Od 26 maja 2020 roku Rozporządzenie Parlamentu Europejskiego i Rady 2017/745 w sprawie wyrobów medycznych 
(dalej zwane „MDR”) będzie podlegać stosowaniu w Polsce. Regulacja zastąpi przepisy krajowe uchwalone na podsta-
wie dotychczasowego systemu dyrektyw o wyrobach medycznych („MDD”). Obowiązująca obecnie ustawa o wyrobach 
medycznych zostanie uchylona i zastąpiona nową ustawą (projekt jest obecnie konsultowany). Nowe przepisy zmienią 
warunki prowadzenia badań obserwacyjnych, nieinterwencyjnych, w których wyroby medyczne są stosowane zgodnie 
z przeznaczeniem producenta (in-label). Dzisiejsze prawo przewiduje liberalne podejście do tego rodzaju badań, jednak 
od maja 2020 roku zaczną one przypominać pełne badania kliniczne, z wyjątkiem obowiązku uzyskania pozwolenia 
administracyjnego. W artykule opisano ten problem, a także podano argumenty na rzecz tezy, że mimo wątpliwości takie 
badania nie będą wymagały uprzedniej opinii komisji bioetycznej.
Słowa kluczowe: wyroby medyczne, ocena kliniczna, badanie kliniczne
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